BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Special

Scientific Infrastructure or Expensive Theatre? AI Discovery’s Reckoning in Asia

In October 2025, Eli Lilly announced it would build the most powerful supercomputer ever owned by a drug company. By February 2026, “LillyPod” ...

June 02, 2026 | Analysis

When America Builds a Wall: Who Inherits China’s Displaced Biotech Work?

When President Trump signed the FY2026 National Defense Authorization Act on December 18, 2025, the biopharmaceutical industry finally got the law it had s...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

Quantum Breakthrough Enables Largest Ever Protein Simulations Advancing Drug Discovery Potential

Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE: IBM) have used IBM quantum computers and two of the world's most powerful supercomputers to simu...

May 06, 2026 | News

Alar Pharmaceuticals Reports Positive Phase 1 Results For ALA 3000 In Treatment Resistant Depression

By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, impr...

April 08, 2026 | News

From Staging to Survival: How AI-Driven Histological Analysis Is Solving Colorectal Cancer's Overtreatment Problem

The hidden cost of getting treatment decisions wrong Colorectal cancer (CRC) is one of the most prevalent and lethal cancers worldwide, ranking among the ...

April 02, 2026 | Expert Insight | By Dr. Torbjørn Furuseth, CEO and Co-Founder, DoMore Diagnostics

Taiwan Strengthens Its Position In Asia’s Next Phase Of Bioprocessing Growth

Taiwan’s bioprocessing and biotechnology sector has moved from a predominantly research-and-services footing toward a more industrialised, globally c...

March 20, 2026 | Analysis

From Concept to Validation-Ready: How Nelipak’s Singapore Hub Aims to Accelerate APAC Healthcare Packaging to Global Scale

Nelipak Healthcare Packaging has launched a new Asia-Pacific Technical Development Center in Singapore, establishing an integrated hub that unites ...

March 17, 2026 | Interaction

2026: AI Transforms China’s Pharma Sector and Drives More Strategic M&A Deals

The preceding decade was marked by rapid growth and robust policy backing; however, the landscape has fundamentally evolved. Research and development expen...

March 13, 2026 | Opinion | By By Adam Zhang Yu, Founder & CEO, Collabrium Partners

Sciwind Biosciences And Pfizer China Forge Strategic Commercialisation Pact For Ecnoglutide In Mainland China

Hangzhou Sciwind Biosciences Co., Ltd. announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a n...

February 25, 2026 | News

New England Biolabs Showcases Automation Ready NGS Workflows Through Global SLAS Collaborations

New England Biolabs (NEB ®) will present several scientific posters at this week's Society for Laboratory Automation and Screening (SLAS) meeting in Bo...

February 09, 2026 | News

Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership

In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational...

February 02, 2026 | Expert Insight

China Originated Innovation Is Rising. Global Expectations Are Rising Even Faster.

The momentum is real—and so is the level of scrutiny. As more programs move beyond regional boundaries, expectations from global biopharma companies ...

February 02, 2026 | News | By Anil Kane, executive director, global head of technical and scientific affairs, Thermo Fisher Scientific

From Capacity to Capability: How 2026 can be the catalyst for what APAC’s Biopharma Growth Needs Next

Beyond Scale: What Will Sustain APAC’s Biopharma Leadership Asia-Pacific’s rise in global biopharma is no longer about whether the region can ...

January 21, 2026 | News | By Joonho Choi, Vice President, Asia-Pacific, Cytiva

Navigating European Regulatory and Market Access Pathways: Crucial Considerations from TMC’s Catherine Moncad

As more APAC biotech and pharma companies look to Europe for regulatory approval and commercialisation, navigating complex EU and UK requirements early is ...

January 19, 2026 | News

Stay Connected